MedTrace Logo

Evaluating Liraglutide in Alzheimer's Disease

NCT01843075 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 204

Last updated 2019-06-10

No results posted yet for this study

Summary

This is a 12-month, multicentre randomised double-blind placebo-controlled Phase IIb study in patients with mild Alzheimer's dementia (AD). Patients will be randomised on a 1:1 ratio to receive liraglutide or matching placebo.

Conditions

Interventions

DRUG

Liraglutide

Daily subcutaneous injection

DRUG

Placebo

Daily subcutaneous injection

Sponsors & Collaborators

  • King's College Hospital NHS Trust

    collaborator OTHER

  • University of Oxford

    collaborator OTHER

  • University of Southampton

    collaborator OTHER

  • Avon and Wiltshire Mental Health Partnership NHS Trust

    collaborator OTHER_GOV

  • Imperial College London

    lead OTHER

Principal Investigators

  • Paul Edison, PhD FRCPI · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2019-12-31
Completion
2019-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01843075 on ClinicalTrials.gov